Treatment Patterns and Healthcare Costs in Newly Diagnosed Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As First-Line Therapy in the United States: A Retrospective Claims Database Analysis

被引：0
|
作者：
Chen, Lei [1 ]
Latremouille-Viau, Dominick [2 ]
Guerin, Annie [2 ]
Nitulescu, Roy [2 ]
Gagnon-Sanschagrin, Patrick [2 ]
机构：
[1] Novartis Pharmaceut, E Hanover, NJ USA
[2] Anal Grp Inc, Montreal, PQ, Canada
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States
    Latremouille-Viau, Dominick
    Guerin, Annie
    Nitulescu, Roy
    Gagnon, Patrick S.
    Joseph, George J.
    Chen, Lei
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (01) : 63 - 71
  • [2] Comparison of Healthcare Resource Utilization and Costs Related to Infections between Patients Newly Diagnosed with Chronic Myeloid Leukemia Treated with Dasatinib and Nilotinib As First-Line Therapy in the United States
    Seiter, Karen
    Latremouille-Viau, Dominick
    Guerin, Annie
    Ndife, Briana
    Habucky, Karen
    Joseph, George J.
    Pivneva, Irina
    Gagnon-Sanschagrin, Patrick
    Tang, Derek H.
    BLOOD, 2017, 130
  • [3] Nilotinib and Dasatinib in the First-Line Therapy for chronic myeloid Leukemia
    Pretscher, Dominik
    Wilhelm, Martin
    MEDIZINISCHE KLINIK, 2010, 105 (08) : 588 - 588
  • [4] COMPARISON OF HEALTHCARE RESOURCE UTILIZATION (HRU) AND COSTS RELATED TO PLEURAL EFFUSION (PE) BETWEEN PATIENTS NEWLY DIAGNOSED WITH CHRONIC MYELOID LEUKEMIA (CML) TREATED WITH DASATINIB OR NILOTINIB AS FIRST-LINE THERAPY IN THE UNITED STATES
    Seiter, K.
    Latremouille-Viau, D.
    Guerin, A.
    Ndife, B.
    Habucky, K.
    Joseph, G. J.
    Pivneva, I
    Gagnon-Sanschagrin, P.
    Tang, D. H.
    VALUE IN HEALTH, 2018, 21 : S28 - S28
  • [5] First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
    Guoqing Wei
    Shamudheen Rafiyath
    Delong Liu
    Journal of Hematology & Oncology, 3
  • [6] First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
    Wei, Guoqing
    Rafiyath, Shamudheen
    Liu, Delong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2010, 3
  • [7] Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States
    Seiter, Karen
    Latremouille-Viau, Dominick
    Guerin, Annie
    Ndife, Briana
    Habucky, Karen
    Tang, Derek H.
    Pivneva, Irina
    Gagnon-Sanschagrin, Patrick
    Joseph, George J.
    ADVANCES IN THERAPY, 2018, 35 (10) : 1671 - 1685
  • [8] A Retrospective Analysis of Treatment Patterns in Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As Second-Line Therapy after Imatinib
    Smith, B. Douglas
    Liu, Jun
    Latremouille-Viau, Dominick
    Zhou, Zhou
    Guerin, Annie
    Fernandez, Daniel
    Yi, Dingdong
    Wang, Xufei
    Wu, Eric Q.
    Mhatre, Shivani K.
    Keir, Christopher H.
    Chen, Lei
    BLOOD, 2014, 124 (21)
  • [9] Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States
    Karen Seiter
    Dominick Latremouille-Viau
    Annie Guerin
    Briana Ndife
    Karen Habucky
    Derek H. Tang
    Irina Pivneva
    Patrick Gagnon-Sanschagrin
    George J. Joseph
    Advances in Therapy, 2018, 35 : 1671 - 1685
  • [10] Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis
    Noriyoshi Iriyama
    Kei-Ji Sugimoto
    Eriko Sato
    Tomoiku Takaku
    Michihide Tokuhira
    Tomonori Nakazato
    Maho Ishikawa
    Hiroyuki Fujita
    Isao Fujioka
    Yuta Kimura
    Norio Asou
    Masahiro Kizaki
    Norio Komatsu
    Yoshihiro Hatta
    Tatsuya Kawaguchi
    Medical Oncology, 2018, 35
12345